Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Multifocal choroiditis with panuveitis Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Multifocal choroiditis with panuveitis indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Acute posterior multifocal placoid pigment epitheliopathy Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Acute posterior multifocal placoid pigment epitheliopathy indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Mucous membrane pemphigoid with ocular involvement Indication Strategy Report 2026: C5, Trials and Deals
3 August 2026
2026 Mucous membrane pemphigoid with ocular involvement indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Erythrodermic psoriasis Indication Strategy Report 2026: IL-17, Trials and Deals
3 August 2026
2026 Erythrodermic psoriasis indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Acrodermatitis continua of Hallopeau Indication Strategy Report 2026: IL-36R, Trials and Deals
3 August 2026
2026 Acrodermatitis continua of Hallopeau indication strategy covering epidemiology, IL-36R biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Acute generalized exanthematous pustulosis Indication Strategy Report 2026: IL-36, Trials and Deals
3 August 2026
2026 Acute generalized exanthematous pustulosis indication strategy covering epidemiology, IL-36 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Drug reaction with eosinophilia and systemic symptoms Indication Strategy Report 2026: IL-5, Trials and Deals
3 August 2026
2026 Drug reaction with eosinophilia and systemic symptoms indication strategy covering epidemiology, IL-5 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Acute cutaneous graft-versus-host disease Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Acute cutaneous graft-versus-host disease indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Toxic epidermal necrolysis Indication Strategy Report 2026: Fas, Trials and Deals
3 August 2026
2026 Toxic epidermal necrolysis indication strategy covering epidemiology, Fas biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Oral chronic graft-versus-host disease Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Oral chronic graft-versus-host disease indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Erosive oral lichen planus Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Erosive oral lichen planus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Lichen planus pemphigoides Indication Strategy Report 2026: IL-17, Trials and Deals
3 August 2026
2026 Lichen planus pemphigoides indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market…